A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Clinical trial NCT01513317 · TERMINATED

Trial details

NCT number: NCT01513317
Sponsor: Janssen Research & Development, LLC
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndrome

Start date: 2011-11-01
Primary completion: 2012-09-01
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.